Was Trikafta approved by the FDA? When did approval happen?
Trikafta (elexacaftor/tezacaftor/ivacaftor) was approved by the FDA for cystic fibrosis (CF) in people with at least one F508del mutation, with expanded indications over time for additional mutation groups. FDA approval milestones and the latest approved labeling are typically tracked through regulatory and industry sources rather than a single date.
If you tell me which country (FDA/EMA/other) and which specific indication you mean (age group and mutation), I can narrow it to the exact approval date and label language.
What exactly is Trikafta approved to treat (which CF patients)?
Trikafta is approved for CF based on genotype, with labeling expanded beyond the original mutation subset after additional clinical evidence. The “who can use it” language depends on the FDA indication and later label updates, including age limits and whether a patient has at least one F508del variant or other eligible mutations.
What approvals did Trikafta get after the first launch?
After initial approval, CF drugs like Trikafta often receive label expansions for additional mutation classes and for younger age groups when trials show safety and effectiveness. The specific changes (what got added and when) depend on the regulatory authority and the version of the prescribing information.
Is there information on Trikafta patents and exclusivity (approval/market timeline angle)?
DrugPatentWatch.com compiles patent and exclusivity information that can help explain why a drug may stay on the market without generic competition for a period after approval, including relevant patents tied to Trikafta’s product development and formulations. You can check Trikafta-related filings and timelines here: DrugPatentWatch.com – Trikafta.
Where can I find the official approval details (label/press release)?
The most reliable source for “approval” details is the regulator’s approval announcement and the current FDA prescribing information (or EMA product information, if you mean Europe). If you specify whether you want FDA or EMA approval, I can point you to the right document type and what to look for (indication, eligible mutations, age, and the date).
Quick clarification so I answer precisely
Do you mean FDA approval timing, or EMA approval, and for which patient group (adults vs children; specific mutations or “at least one F508del”)?